Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 35 articles: HTML format

Single Articles

November 2023
1. WHELAN TJ, Parpia S, Levine MN
   Omitting Radiotherapy in Luminal A Breast Cancer. Reply.
   N Engl J Med. 2023;389:1727-1728.
   PubMed    
   
   
   
2. RECHT A
   Omitting Radiotherapy in Luminal A Breast Cancer.
   N Engl J Med. 2023;389:1727.
   PubMed    
   
   
   August 2023
3. WHELAN TJ, Smith S, Parpia S, Fyles AW, et al
   Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer.
   N Engl J Med. 2023;389:612-619.
   PubMed     Abstract available
   
   
   June 2023
4. TURNER NC, Oliveira M, Howell SJ, Dalenc F, et al
   Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
   N Engl J Med. 2023;388:2058-2070.
   PubMed     Abstract available
   
   
   May 2023
5. GIORDANO SH
   POSITIVE Results for Breast Cancer Survivors Who Desire Pregnancy.
   N Engl J Med. 2023;388:1709-1710.
   PubMed    
   
   
   
6. PARTRIDGE AH, Niman SM, Ruggeri M, Peccatori FA, et al
   Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
   N Engl J Med. 2023;388:1645-1656.
   PubMed     Abstract available
   
   
   March 2023
7. AKHAM R, Hazarika N
   Paget's Disease of the Breast.
   N Engl J Med. 2023;388:1126.
   PubMed    
   
   
   
8. CALLISON K, Pesko MF, Phillips S, Sosa JA, et al
   Cancer Screening after the Adoption of Paid-Sick-Leave Mandates.
   N Engl J Med. 2023;388:824-832.
   PubMed     Abstract available
   
   
   February 2023
9. HO AY, Bellon JR
   Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer.
   N Engl J Med. 2023;388:652-653.
   PubMed    
   
   
   
10. KUNKLER IH, Williams LJ, Jack WJL, Cameron DA, et al
    Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.
    N Engl J Med. 2023;388:585-594.
    PubMed     Abstract available
    
    
    October 2022
11. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    PubMed    
    
    
    
12. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    PubMed    
    
    
    
13. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    PubMed    
    
    
    September 2022
14. MODI S, Gambhire D, Cameron D
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
    N Engl J Med. 2022;387:1145-1146.
    PubMed    
    
    
    
15. CARROLL HK, Higgins MJ, O'Reilly S
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1144.
    PubMed    
    
    
    
16. SCHNOG JB, Samson MJ, Duits AJ
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1143-1144.
    PubMed    
    
    
    August 2022
17. CHRISTIAN NT, Borges VF
    What Dobbs Means for Patients with Breast Cancer.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
    PubMed    
    
    
    July 2022
18. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    PubMed    
    
    
    
19. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    PubMed     Abstract available
    
    
    
20. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    
    
    
    June 2022
21. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    
    
    
    
22. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    
    
    
    
23. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    
    
    
    
24. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available
    
    
    May 2022
25. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    
    
    
    
26. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    
    
    
    March 2022
27. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available
    
    
    
28. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available
    
    
    February 2022
29. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available
    
    
    December 2021
30. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    
    
    
    
31. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available
    
    
    October 2021
32. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    
    
    
    
33. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    
    
    
    
34. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    
    
    
    September 2021
35. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.